The European Respiratory Virus Surveillance Summary (ERVISS)
This interactive dashboard provides a weekly integrated epidemiological summary for influenza, RSV and severe acute respiratory syndrome coronavirus 2 for the EU/EEA and the WHO European Region
EU Countries miss flu vaccination target (except for one)
European health ministers agreed on a target of vaccinating 75% of older people in 2009 ‒ almost all countries are still falling short.
Why Vaccinate Healthy 2- to 17-Year-Olds Against Influenza?
On February 2023, the French National Authority for Health (HAS) recommended extending flu shots to children aged 2-17 years without comorbidities.
News
Policy & Recommendations
Policy Recommendations for Empowering healthcare professionals for everyone’s protection
Steering Group on Influenza Vaccination releases on the EU Flu Day a set of Policy Recommendations for the EU and national governments to expand influenza vaccine uptake.
Seasonal influenza vaccination recommendations and coverage rates in EU/EEA Member States
An overview of vaccination recommendations for 2021-22 and coverage rates for the 2018–19 to 2020–21 influenza seasons.
WHO/Europe, EC and ECDC urge eligible groups to get vaccinated or boosted to save lives this autumn and winter
Last year’s autumn and winter seasons were unpredictable. Last winter, the cumulative impacts of influenza, COVID-19, and respiratory syncytial virus or RSV hit the very young and the very old the hardest.
|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
Australian discovery of change in ‘killer T cells’ could help fight against influenza
Research led by Dr Carolien van de Sandt, a senior research fellow at the Doherty Institute and 2023 Claude Hannoun Prize, and UNSW Sydney shows that cells are replaced as we get older by ones less able to read threat from infections
Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season
WHO convenes technical consultations in February and September each year to recommend viruses for inclusion in influenza vaccines for the northern hemisphere (NH) and southern hemisphere (SH) influenza seasons, respectively.
Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases
Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan
CD8+ T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear.